Abstract: Objective To investigate the clinical efficacy of stereotactic body radiation therapy (SBRT) on liver metastases.  Methods The clinical data of 43 patients with liver metastases admitted to Shanghai East Hospital of Tong Ji University from December 2016 to May 2020 were retrospectively analyzed. All the patients underwent 4D-CT or respiration gating for CT simulation; a total of 58 lesions received SBRT, with a radiation dose of 36-70 Gy; the number of splits was 5-10 times, once a day and 5 times a week. Results A total of 43 patients successfully completed the whole course of radiationtherapy. The median follow-up time was 15.6 months (range: 2.0-31.9 months). The 2-year overall survival rate, local control rate and progression-free survival rate were 55.4％, 86.0％ and 5.9％, respectively. The common grade Ⅰ-Ⅱadverse reactions were anorexia (6 cases), fatigue (6 cases), myelosuppression (3 cases) and-liver pain (1 case), respectively, and no grade Ⅲor above was found. The average score of the EQ-5D-5L quality of life questionnaire was 0.848 (with a standard deviation of 0.277). Conclusions SBRT on liver metastases can obtain better local control rate and fewer adverse reactions. Its long-term efficacy and safety deserve further exploration in randomized controlled trials.

Key words: Liver cancer, Liver metastases, Stereotactic body radiation therapy, Clinical efficacy